Zhihong Chi

机构：Peking University, Peking University Cancer Hospital, Ministry of Education · ORCID：0000-0001-6257-6775

发表论文 320 篇 · 总被引 7020 次 · h-index 43

代表论文

• Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial (2024 · Signal Transduction and Targeted Therapy · 被引 38)
• Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study. (2023 · Journal of Clinical Oncology · 被引 25)
• Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study (2025 · Med · 被引 16)
• Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial (2024 · Journal for ImmunoTherapy of Cancer · 被引 14)
• A nomogram incorporating Ki67 to predict survival of acral melanoma (2023 · Journal of Cancer Research and Clinical Oncology · 被引 14)
• Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody ( TQB2450 ) in patients with advanced acral melanoma (2023 · Journal of the European Academy of Dermatology and Venereology · 被引 13)